Tasneem P. Sharma, PhD
Assistant Professor of Ophthalmology
Adjunct Assistant Professor of Pharmacology & Toxicology
- Address
-
GK 305U
OPTH
IN
Indianapolis, IN - PubMed:
-
Bio
Dr. Sharma received her bachelor’s degree from University of Texas at Arlington and her doctoral degree from University of North Texas Health Science center. She completed her postdoctoral training at University of Iowa under Dr. Budd Tucker and her second postdoctoral work under Dr. Colleen McDowell. She joined Indiana University School of Medicine as an Assistant Professor within the Department of Ophthalmology and adjunct appointments in Pharmacology and Toxicology. Her research focuses on understanding intraocular and intracranial pressure associated pathogenesis in glaucoma and Spaceflight Associated Neuro-ocular Syndrome, generation of patient specific neuronal cells, disease modeling of central nervous system diseases, and neuroprotection/regeneration therapeutics.
The Sharma Lab Website: https://www.sharmaneurolab.com/
PROFESSIONAL MEMBERSHIPS
2019-present ISER - International Society for Eye Research
2013-present Sigma Xi – The Scientific Research Society Member
2003-present WEAVR- Women in Eye And Vision Research
2011-present AOPT - Association for Ocular Pharmacology and Therapeutics
2009-present AAAS - American Association for the Advancement of Science
2009-present ARVO - Association for Research in Vision and Ophthalmology
Key Publications
- Hameed S. S., Sharma T. P. Generation of Retinal Ganglion Cells from Reprogrammed Keratocytes of Non-glaucoma and Glaucoma donors, Curr Protoc. 2025 Jan;5(1):e70091.doi: 10.1002/cpz1.70091.
- Hameed S.S., Bodi N.E., Miller R.C., Sharma T.P. Neuritin 1 drives therapeutic preservation of retinal ganglion cells in an ex-vivo human glaucoma model. J Ocul Pharmacol Ther. 2024 Jul 12. doi: 10.1089/jop.2024.0041.
- Ho K., Bodi, N. E., Sharma T.P. Normal-Tension Glaucoma and Potential Clinical Links to Alzheimer’s Disease. J. Clin. Med. 2024, 13(7), 1948.
- Soucy, J.R., et al. Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium. Mol Neurodegeneration18, 64, 2023.
- Peng M., Curry, S. M, Liu, Y., Lohawala, H., Sharma G., Sharma T.P. The Ex-Vivo Human Translaminar Autonomous System to Study SANS Pathogenesis. npj Microgravity volume 8, Article number: 44 2022
- Peng M., Margetts T. J., Sugali C.K., Rayana N.P., Dai J., Sharma T.P., Raghunathan V. K., Mao W. An ex vivo model of human corneal rim perfusion organ culture. Exp Eye Res. 2022 Jan;214: 108891.
- Peng M., Park B., Harikrishnan H., Jahan S., Dai J., Rayana N.P., Sugali C.K., Sharma T.P., Imanishi S., Imanishi Y., Corson T. W., Mao W. A smartphone-based method for mouse fundus imaging. Exp Eye Res. 2021 May; 206:108530.
- Sharma, T. P., Curry, S. M., Lohawala, H., McDowell, C. Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments. J. Vis. Exp. (158), e61006, 2020.
| Year | Degree | Institution |
|---|---|---|
| 2014 | PhD | University of North Texas |
| 2006 | BS | University of Texas |
My research program entails focusing on intraocular and intracranial pressure associated pathogenesis, generation of patient specific neuronal cells, disease modeling of central nervous system diseases, and neuroprotection/regeneration therapeutics. Currently I am developing a range of new glaucoma therapeutics for neuroprotection and pharmacological manipulations of degenerative pathways in glaucoma. Our current studies will identify pathways or molecules that can best be treated with drugs that are beyond intraocular pressure suppression and instead focus on survival of retinal ganglion cells. My scientific and scholastic concentrations comprise stem cell biology, 3D differentiation, neuroregeneration and therapeutics. During my scientific career, I have focused on the successful generation of patient-specific induced pluripotent stem cells (iPSCs) for cell-based therapy and development of different neuronal subtypes for treating degenerative diseases. Our lab has expertise in organ-based disease modeling, CRISPR-based genome editing technology, RNA-Seq and bioinformatics analysis. Additionally, I have invented and generated the Translaminar Autonomous System which is currently under a patent. This model allows me to study effects of translaminar pressure on iPSC-derived retinal ganglion cells and their axons, permitting me to test novel targets that exhibit neuroprotection and regeneration. In addition, we have received funding from the NASA-affiliated consortium, the Translational Research Institute for Space Health to characterize the Space Associated Neuro-ocular syndrome using my patent pending model.
PATENTS APPLICATIONS FILED
Translaminar Autonomous System: A model to allow modulation of translaminar pressure in a donor human posterior eye cup. The intraocular and intracranial pressure can be altered independently of each other using this model system. Patent application filed on April 26, 2019 under U.S. Patent Application No. 16/395,610. https://patents.google.com/patent/US20190327958A1/en?oq=16%2f395%2c610
Desc: Outstanding Faculty Commitment to Diversity Award
Scope: School
Date: 2023-09-01